Evidence map›Paper›PMID 36679627›Full record

ArticleSensors (Basel, Switzerland)2023

Multidimensional Biomechanics-Based Score to Assess Disease Progression in Duchenne Muscular Dystrophy.

Carolina Migliorelli, Meritxell Gómez-Martinez, Paula Subías-Beltrán, Mireia Claramunt-Molet, Sebastian Idelsohn-Zielonka, Eudald Mas-Hurtado, Felip Miralles, Marisol Montolio, Marina Roselló-Ruano, Julita Medina-Cantillo

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Carolina MigliorelliUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.ORCID 0000-0003-2781-8841
Meritxell Gómez-MartinezUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.
Paula Subías-BeltránUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.
Mireia Claramunt-MoletUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.
Sebastian Idelsohn-ZielonkaUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.ORCID 0000-0002-3721-2774
Eudald Mas-HurtadoUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.
Felip MirallesUnit of Digital Health, Eurecat, Centre Tecnològic de Catalunya, 08005 Barcelona, Spain.
Marisol MontolioDuchenne Parent Project, 28032 Madrid, Spain.
Marina Roselló-RuanoDuchenne Parent Project, 28032 Madrid, Spain.
Julita Medina-CantilloUnidad de Patología Neuromuscular, Servicio de Rehabilitación, Hospital Sant Joan de Déu Barcelona, Passeig Sant Joan de Déu, 2, 08950 Esplugues de Llobregat, Spain.
Centre Tecnologic de Telecomunicacions de Catalunya · ESUniversitat de Barcelona · ESHospital Sant Joan de Déu Barcelona · ES

Funding

EIT Health European network, the Innovation by Ideas program 19260/20686
6 · The paper itself

Abstract

(1) Background: Duchenne (DMD) is a rare neuromuscular disease that progressively weakens muscles, which severely impairs gait capacity. The Six Minute-Walk Test (6MWT), which is commonly used to evaluate and monitor the disease's evolution, presents significant variability due to extrinsic factors such as patient motivation, fatigue, and learning effects. Therefore, there is a clear need for the establishment of precise clinical endpoints to measure patient mobility. (2) Methods: A novel score (6M+ and 2M+) is proposed, which is derived from the use of a new portable monitoring system capable of carrying out a complete gait analysis. The system includes several biomechanical sensors: a heart rate band, inertial measurement units, electromyography shorts, and plantar pressure insoles. The scores were obtained by processing the sensor signals and via gaussian-mixture clustering. (3) Results: The 6M+ and 2M+ scores were evaluated against the North Star Ambulatory Assessment (NSAA), the gold-standard for measuring DMD, and six- and two-minute distances. The 6M+ and 2M+ tests led to superior distances when tested against the NSAA. The 6M+ test and the 2M+ test in particular were the most correlated with age, suggesting that these scores better characterize the gait regressions in DMD. Additionally, the 2M+ test demonstrated an accuracy and stability similar to the 6M+ test. (4) Conclusions: The novel monitoring system described herein exhibited good usability with respect to functional testing in a clinical environment and demonstrated an improvement in the objectivity and reliability of monitoring the evolution of neuromuscular diseases.

Indexed as

Muscular Dystrophy, DuchenneBiomechanical PhenomenaDisease ProgressionHumansReproducibility of ResultsWalkingbecker muscular dystrophybiomechanicsbiomechanics data analysisDuchenne muscular dystrophygaitnorth star ambulatory assessmentsix minute-walk test

Identifiers

PMID36679627
PMCPMC9861677
OpenAlexW4315570812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.